In addition, several reports show that the SARS-CoV-2 Nucleoprotein is a good target for vaccine development as it is conserved and stable, presents fewer mutations over time, is abundant during infection, and is highly immunogenic [59], characteristics that could explain the statistically significant increase in the percentage of activated CD4+ and CD8+ T cells when stimulated with the purified N-SARS-CoV-2 protein at a higher concentration. The gene discussed is CD8A; the disease is infection.